Background pharmaceutical differences in central hemodynamics might influence cardiac response to antihypertensive treatment despite similar lowering of brachial blood pressure (Bp).
Reduction of brachial blood pressure (BP) to guideline target is the established standard for evaluating effects of pharmacological antihypertensive strategies. Several drugs can achieve this goal and consequently many different pharmacological targets are in play. The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study showed that similar BP reduction can be achieved by choosing either β1 receptor blocker or angiotensin II-receptor antagonist based treatment. However, in the LIFE study similar reduction in brachial BP by losartanvs. atenolol-based therapy had better effects on several outcome variables including stroke, atrial fibrillation and reduction of left ventricular (LV) hypertrophy. [1] [2] [3] Therefore, differences exist among antihypertensive drugs in the ability to reduce adverse outcome despite similar brachial BP reduction. Recent studies have shown that these differences are particularly present in patients with competing risks such as diabetes. 4 In the Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation (SAMPLE) study, which reduced office and 24-h BP similarly, organ damage was more dependent on differences in 24-h BP. 5 In a LIFE substudy 24-h ambulatory BP reduction was similar in losartan-and atenolol-treated patients. 6 Furthermore, the Conduit Artery Function Evaluation (CAFE) study showed that despite similar brachial systolic BP on the two treatment-strategies, central aortic pressures were reduced more in amlodipine/perindopril as compared with atenolol/thiazide-treated patients. 7 On the basis of these findings and the relation of central aortic pressure to adverse outcomes, Williams et al. 8 suggested that differences in outcome between the two study arms in the Anglo-Scandinavian Cardiac Outcomes trial (ASCOT) could be because of differences in central hemodynamic features, although this has been controversial. In order to elucidate hemodynamic differences further, we investigated the effects on systemic hemodynamics of losartan-vs. atenolol-based antihypertensive therapy in long-term follow-up of hypertensive patients with LV hypertrophy.
Methods
Study population. The LIFE study was a prospective, randomized, double-blind, parallel group study using the double-dummy technique to evaluate the long-term effects of randomized losartan-or atenolol-based antihypertensive therapy, in patients aged 55-80 years with hypertension and electrocardiographic LV hypertrophy when treated to a target BP <140/90 mm Hg. All patients were followed up for a minimum of 4 years (mean 4.8 years). The main outcome and the complete study protocol, including study design, organization, clinical measures, exclusion criteria, basis for choice of comparative agents, statistical considerations and baseline characteristics have been published. 1, 9, 10 As part of the LIFE study protocol, centers for the LIFE echocardiography substudy were chosen on the basis of established expertise in quantitative echocardiography, with the goal of achieving approximately proportionate representation from the participating countries. Participants in the LIFE echocardiography substudy (n = 960) were comparable with the main LIFE study in age, BP and prevalences of cardiovascular diseases and diabetes at baseline but differed from the remaining LIFE participants in being disproportionately male. Patients enrolled in the LIFE echocardiographic substudy, received 1-2 weeks of placebo after which echocardiography was performed at baseline and then annually for 4 years. The present study uses data from all participants in this substudy with Doppler echocardiographic measurements of stroke volume at baseline and at least one annual in-treatment reexamination (n = 801), to examine the comparative effects of losartan-vs. atenolol-based therapy on hemodynamic parameters. This study complies with the Declaration of Helsinki, locally appointed ethics committees approved the research protocol and informed consent was obtained. The LIFE study is registered with clinicaltrials.gov, unique identifier NCT00338260
Echocardiography. Procedures and reproducibility for echocardiographic LV and atrial measurements have been published previously. 3 Test-retest reproducibility of pulse pressure/stroke index (PP/SI), examined in a separate group of 156 hypertensive patients who underwent echocardiography 2-4 weeks apart whereas off antihypertensive medication, showed fair reproducibility of PP/SI (intraclass correlation coefficient = 0.46). 11 All echocardiograms were read centrally at Cornell Medical Center following recommendations of the American Society of Echocardiography first by trained physicians and then by a highly experienced investigator (R.B.D in 89%). 12, 13 Hemodynamic variables. Peripheral BP was measured by arm cuff sphygmomanometer using a standardized procedure described in the LIFE study protocol. 9 Echocardiographic variables were obtained as stated above. Mean BP was calculated as diastolic BP + 1/3 × (systolic BP -diastolic BP). Stroke volume was calculated from the pulsed Doppler time-velocity integral of flow at the aortic annulus and the aortic annular diameter from 2-dimensional long-axis views, 14 allowing computation of SI (stroke volume/body surface area) and cardiac index (CI (CI = SI × heart rate)). Mean arterial pressure was used with CI to calculate total peripheral resistance index (TPRI), and peripheral PP was divided by SI to yield the PP/SI ratio, an index of global conduit artery stiffness. 15 Systolic function was assessed by dividing midwall shortening by the level predicted for measured circumferential end-systolic stress, termed stress-corrected midwall shortening, used as a measure of myocardial contractility. 16 Diastolic function was assessed by measurement of isovolumic relaxation time, mitral valve E/Aratio and mitral valve deceleration time. 17 Endpoint. The primary endpoint was a composite of the first of nonfatal clinically evident acute myocardial infarction, nonfatal stroke, or cardiovascular death. Endpoints were classified by an endpoint committee blinded to the intervention, using a prespecified manual prepared by the LIFE Steering Committee. 9 Statistical analysis. Data were analyzed using Statistical Analytical Software version 9.2 (SAS, Cary, NC). Data are expressed as mean ± SD. Continuous variables were assessed by skewness statistics and visual inspection of distributions for normality, all variables had near normal distribution in the study population and no transformation was performed, after which baseline differences in continuous variables in the two study arms were assessed by the student-t test and by χ 2 analysis for categorical data. Longitudinal hemodynamic differences (i.e., alterations in SI, CI, TPRI, and global conduit artery stiffness from baseline to last available value during 4 years of treatment) were evaluated by testing for equal intercepts (cumulative mean by treatment) and equal slopes (treatment × time) in atenolol-and losartan-treated using a mixed model with repeated measures. Multivariable differences in the annually estimated echocardiographic hemodynamic variables were evaluated by testing for equal intercepts (without any interaction terms) when adding changes in heart rate, LV internal diameter in diastole (LVIDd), add-on hydrochlorthiazide (HCTZ) and/or calcium channel blockers to the model. To account for hemodynamic effects of nonfatal cardiovascular events, the last value before an acute myocardial infarction or nonfatal stroke was used as the final in-treatment value. The relations of randomized treatment to changes in echocardiographic estimates of cardiac hypertrophy and diastolic function were assessed in a separate mixed model, considering intra-patient variability in repeated measures from baseline to year 4 of randomized treatment (with respect to randomized treatment and concomitant changes in SI and TPRI). To assess whether contrasting hemodynamics mediated any difference in risk of the LIFE composite endpoint, a Cox time-to-event model was fitted using the last known values before event or censoring (controlling for randomized treatment). For hypotheses testing a two-tailed P < 0.05 was required for statistical significance.
results

Baseline hemodynamics and echocardiographic characteristics
Data were available in 801 patients; subjects without data (n = 159) were on average 1.9 ± 0.6 years older (P = 0.002), but had similar systolic and diastolic BP as well as proportion of women (all P > 0.66). Among patients with available data, random treatment allocation was maintained; atenolol-based treatment was associated with slightly higher mitral E/A ratio (P = 0.04), but none of the other investigated hemodynamic and echocardiographic variables differed significantly between the two study arms (all P > 0.27, Table 1 ).
Brachial blood pressure changes during antihypertensive treatment
Mean arterial pressure decreased equally in both treatment arms ( Figure 1) ; cumulative means of brachial systolic and diastolic BP were 0.7 lower and 0.7 mm Hg higher on atenolol based treatment, respectively (all P > 0.18 and >0.07 for equal intercepts and slopes, respectively).
systemic hemodynamic changes during antihypertensive treatment
Unadjusted mean difference in repeated measures of central hemodynamic parameters and heart rate from baseline to last known in-treatment value on losartan-vs. atenolol-based treatment were; 1.8 ml/m 2 (95% confidence interval, 0.9-2.7 ml/m 2 ) lower SI, 5.7 beats/min (95% confidence interval, 4.5-6.9 beats/ min) higher heart rate, 0.183 l/min/m 2 (95% confidence interval, 0.116-0.250 l/min/m 2 ) greater CI, 287 dynes/sec −5 /cm/m 2 (95% confidence interval, 173-401 dynes/sec −5 /cm/m 2 ) lower TPRI (all P < 0.001 and <0.004 for equal intercepts and slopes, respectively), whereas the intercept and slope of change in PP/ SI, as a measure of global conduit artery stiffness, were comparable in the two arms (cumulative mean was 0.04 mm Hg/ ml/m 2 [95% confidence interval, −0.01-0.05 mm Hg/ml/m 2 ] higher on losartan-based treatment, P = 0.08 and 0.52 for equal intercepts and the interaction of treatment group × year of follow-up, respectively). Annual mean values of SI, CI, and TPRI, compared by treatment strategy, are given in Figures 2-4 , respectively.
The lower SI on losartan-based treatment remained significant when adjusting for the individual changes in heart rate, LVIDd, add-on of HCTZ and/or a calcium channel blocker (cumulative mean difference in SI 1.2 ml/m 2 , P = 0.01). Add-on of HCTZ and/or a calcium channel blocker was not independently associated with differences in SI (cumulative means of SI were 0.8 ml/m 2 and 0.4 ml/m 2 , both P > 0.14, higher in those who received add-on HCTZ and/or calcium channel blockers, respectively). In repeated measures of CI, atenolol-vs. losartan-based treatment remained significantly associated with lower CI when adjusting for intra-patient variability in heart rate, LVIDd, add-on of HCTZ and/or a calcium channel blocker (cumulative mean difference in CI 0.128 l/min/ m 2 , P < 0.001). Add-on of HCTZ but not of a calcium channel blocker was independently associated with higher CI (cumulative mean of CI was 0.083 l/min/m 2 and higher in those who received add-on HCTZ, P = 0.04, vs. 0.049 l/min/m 2 higher in those who received add-on calcium channel blockers, P = 0.06). A similar model showed that TPRI remained significantly lower on losartan treatment when adjusting for the individual differences in heart rate, LVIDd, add-on of HCTZ and/ or a calcium channel blocker (cumulative mean difference 187 dynes/sec −5 /cm/m 2 , P = 0.001). Add-on of HCTZ and/or a calcium channel blocker was not independently associated with differences in TPRI (cumulative mean of TPRI was 84 dynes/ sec −5 /cm/m 2 lower in those who received add-on HCTZ vs. 60 dynes/sec −5 /cm/m 2 lower in those who received add-on calcium channel blockers, both P > 0.19). The non-significant difference in repeated measures of PP/SI was further attenuated by adjusting for intra-patient variability in heart rate, LVIDd, add-on of HCTZ and/or a calcium channel blocker (cumulative mean was 0.03 mm Hg/ml/m 2 higher on losartan-based treatment, P = 0.19).
cardiac hypertrophy, systolic and diastolic function during antihypertensive treatment
In repeated measures from baseline to year 4 of follow-up, losartan-vs. atenolol-based treatment was associated with more favorable systolic-and diastolic performance indexes; losartan treatment was associated with 1.7% (95% confidence interval, −0.5 to −2.9%) lower stress-corrected midwall shortening (expressed as % of predicted), 0.11 lower mitral E/A ratio (95% confidence interval, −0.08 to −0.15), ~0.1 cm smaller left atrial systolic diameter (95% confidence interval, −0.02 to −0.15 cm) as well as a steeper improvement in isovolumic relaxation time (all P < 0.04; Table 2 ). However, when adjusting for the divergent changes in SI and TPRI, the differences in systolic-and diastolic function indexes were attenuated ( Table 3) CI, confidence interval; LV, left ventricular. *P value for equal intercepts (difference in averaged mean by treatment group). **P value for equal slopes (difference in relative changes by treatment group). treatment was only associated with a smaller left atrial diameter (cumulative mean difference 0.07 cm; 95% confidence intervals, −0.13 to −0.01, P = 0.03, Table 3 ).
hemodynamic parameters and cardiovascular event rate during antihypertensive treatment
A total of 66 primary events (8.2%) occurred in the composite endpoint. Using the last available in-treatment values, lower SI, CI, and LV mass/body surface area (all P < 0.02) but not heart rate in itself predicted the primary endpoint (P = 0.46, Table 4 ). The predictive values of investigated in-treatment hemodynamic parameters of the LIFE composite endpoint did not differ significantly in those randomized to losartanvs. atenolol-based treatment (all P > 0.06). Similarly, there was no detectable difference in rates of the composite endpoint between the two randomized treatments (P = 0.64).
discussion
This study has two new observations on the basis of the fact that similar brachial BP reduction in losartan-vs. atenololbased antihypertensive therapy is achieved through contrasting hemodynamic mechanisms. First, losartan-based treatment preserved CI and substantially reduced TPRI, whereas atenolol-based treatment reduced CI and caused lesser reduction in TPRI. The lowering of TPRI on atenolol-based treatment, which contrasts with findings in some previous studies, may partly reflect diminution of renin-angiotensin system activity by β-blockade. The attenuated difference in SI when adjusting for heart rate indicates an important impact of heart rate reduction in driving the change in SI. These different in-treatment responses extend information from prior studies using sensitive invasive measurement techniques. 18, 19 However, to the best of our knowledge, these hemodynamics differences have not been described in a large population of hypertensive patients with LV hypertrophy during long time follow-up. Second, the present study identifies nearly equal reductions in PP/SI during 4 years of losartan-vs. atenolol-based antihypertensive treatment. This suggests that the differing hemodynamic effects of the two treatment regimens are not mediated by differential effects on arterial stiffness, concurring with pulse wave velocity measurements in the CAFE and REASON study. 7, 20 A mechanism may involve that the substantial reduction of arterial pressure had a greater effect on arterial remodeling and function than did differences in specific effects of the two regimens on progression of atherosclerosis and endothelial function. Furthermore, we have previously shown that there LV, left ventricular; SI, stroke volume index; TPRI, total peripheral resistance index. *P value for equal intercepts (difference in averaged mean by treatment group). **P value for equal slopes (difference in relative changes by treatment group). was no detectable impact on aortic root diameter of treatment with losartan-or atenolol-based regimens. 21 A recent study showed parallel reduction in PP between the two LIFE treatment regimens and that lower in-treatment PP among these high-risk patients predicted higher risk of cardiovascular morbidity and mortality, possibly because of reduced LV systolic function. 22 This suggests that PP and LV function, at least in high-risk patients, are interdependent and as such cannot be considered independently. The pathophysiological basis for lower cardiac index on atenolol-vs. losartan-based treatment (despite greater SI in patients on atenolol-based treatment), involves the greater reduction in heart rate induced by β-blocker therapy.
Prior LIFE analyses have related lower stroke volume to concentric LV remodeling a known predictor of poor prognosis. 23 However, the more recent report of Lønnebakken et al. 24 that lower in-treatment stroke volume independent of LV mass and geometry predicted higher risk of cardiovascular events in LIFE, argues that a reduced stroke volume might be an indicator of adverse vascular remodeling. The higher mean stroke volume and lower heart rate during randomized treatment with atenolol in this study, contrasts with the higher overall cardiovascular event rate in this treatment arm. 1 This argues that in hypertensive patients with LV hypertrophy, the otherwise beneficial effect of slower heart rate on stroke volume may partly blunt the impact of afterload reduction on LV hypertrophy regression. 25 Therefore, in patients similar to those in LIFE, therapy aimed at reducing cardiovascular events should target lowering of LV afterload over heart rate, which seems to be of a relatively greater prognostic importance in ischemic heart failure. 26 A mechanism may involve that in hypertensive patients with LV hypertrophy, reductions in LV afterload improve LV systolic and diastolic performance resulting in more LV hypertrophy regression and better outcome. 3, 27, 28 However, it should be noted that a lower heart rate still seems beneficial in hypertensive patients, as data from the overall LIFE study suggest that the greater rate of the composite endpoint in atenolol-treated patients is not driven by the greater heart rate reduction per se. 29 Similarly, it is hard to quantitate the relative prognostic contributions of hemodynamic parameters, as outcome in the LIFE study related to several mechanisms, some of which were unrelated to changes in hemodynamic status.
Our study has limitations. Although, PP/SI provides a theoretical estimate of the arterial Windkessel function, 30 the arterial system is not a closed circuit and the PP/SI has not been clinically validated as an estimate of arterial stiffness. Nonetheless, assessing the heart-arterial interaction by use of PP/SI and its utility as an approximate index of systemic arterial compliance has been well documented. 25 Assessment of plasma renin activity, arterial pressure wave form or pulse wave velocity was not included in the LIFE study protocol. This study is not powered to assess hemodynamic effects of add-on therapy, which comprised a variety of medications, doses and durations.
In conclusion, in hypertensive patients with LV hypertrophy the hemodynamic mechanism of BP reduction in atenolol treatment is a decrease in heart rate that exceeds the increase in SI, leading to an overall reduction of CI. In losartan-treated patients, a similar decrease in peripheral BP is achieved by a hemodynamically contrasting decrease in TPRI with modest change in SI. Although we were not able to detect a difference in outcome between treatment allocations in this study, we demonstrated that these hemodynamic differences influenced cardiac response to equal peripheral blood pressure lowering. This argues that hemodynamics might be a part of explaining prognostic differences between antihypertensive treatments strategies despite a 0.3 mm Hg difference in reduction of mean brachial BP.
